Lexeo Therapeutics is a New York‑based clinical‑stage genetic medicines company that applies pioneering science to fundamentally change disease treatment. Leveraging research from Weill Cornell Medicine and UC San Diego, the company partners with leading gene‑therapy institutions and follows a stepwise development strategy to advance a pipeline focused on cardiovascular disease and APOE4‑associated Alzheimer’s disease. Early proof‑of‑concept functional and biomarker data guide each program, while a leadership team of pioneers brings decades of experience in genetic medicines, rare‑disease drug development, manufacturing and commercialization. Lexeo’s distinctive combination of cutting‑edge science, strategic collaborations, and seasoned expertise positions it to accelerate the translation of gene‑based therapies into clinical reality.
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases are treated. The Graduate intern will have the opportunity to make significant contributions to Lexeo’s portfolio management systems and strategy, shaping planning, resourcing, budgeting, and risk management for complex gene therapy programs.
Lexeo Therapeutics is a New York‑based clinical‑stage genetic medicines company that applies pioneering science to fundamentally change disease treatment. Leveraging research from Weill Cornell Medicine and UC San Diego, the company partners with leading gene‑therapy institutions and follows a stepwise development strategy to advance a pipeline focused on cardiovascular disease and APOE4‑associated Alzheimer’s disease. Early proof‑of‑concept functional and biomarker data guide each program, while a leadership team of pioneers brings decades of experience in genetic medicines, rare‑disease drug development, manufacturing and commercialization. Lexeo’s distinctive combination of cutting‑edge science, strategic collaborations, and seasoned expertise positions it to accelerate the translation of gene‑based therapies into clinical reality.
Revolution Medicines